NCT01284478View on ClinicalTrials.gov

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Pseudophakic Cystoid Macular Edema,Diabetic Macular Edema
Interventions
DRUG

Dexamethasone Implant

Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally

Trial Locations (1)

94040

Northern California Retina Vitreous Associates, Mountain View

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Northern California Retina Vitreous Associates

OTHER